title: New insights into the mechanism of action of immune checkpoint antibodies.
abstract: Preclinical models have been developed and applied to predict the clinical efficacy of immune checkpoint antibodies. Now these models can be used to dissect the mechanisms by which such immunotherapeutic antibodies work and to build the rationale for combining immune checkpoint-targeting antibodies with potential synergistic activity in cancer patients.
authors.affiliation: Center de Recherche en Cancérologie de Lyon; UMR INSERM U1052 CNRS 5286; Center Léon Bérard; Université de Lyon ; Lyon, France.
authors.forename: Aurélien
authors.initials: A
authors.lastname: Marabelle
authors.affiliation: Division of Oncology; Stanford University; Department of Medicine ; Stanford, CA USA.
authors.forename: Holbrook
authors.initials: H
authors.lastname: Kohrt
authors.affiliation: Division of Oncology; Stanford University; Department of Medicine ; Stanford, CA USA.
authors.forename: Ronald
authors.initials: R
authors.lastname: Levy
keywords: CTLA-4; GITR; OX40; cancer; immune checkpoint antibodies; immunotherapy